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Superoxidendria in cell fate decisions has been well documented over the years. These
observations have highlighted the way mitochondrial physiology controls cell survival and growth in the
normal settings, the critical role of mitochondrial outer membrane permeabilization and altered mitoener-
getics in cell death execution, and most importantly the association of altered mitochondrial metabolism
with pathological states, in particular cancer. Reprogramming of cell metabolism, an invariable ﬁnding in
cancer cells, is tightly linked tomitoenergetics as is evidenced by up-regulation of nutrient uptake and a pro-
oxidant tilt in the intracellular milieu. The latter has also been demonstrated in oncogene-induced
carcinogenesis models, notably as a functional outcome of Bcl-2 overexpression. Interestingly, even in that
model, mitochondria appear to be the target as well. Thus the association of metabolic re-circuiting and
altered mitoenergetics with the process of transformation has resulted in a paradigm shift in the way cancer
development and progression is viewed today, which has tremendous implications for the development of
novel and strategic therapeutic modalities.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionThe role of mitochondria in metabolism is well established. From
metabolic diseases to cancer, the organelle remains a hotbed for
intense research and discovery on themechanisms leading up to these
diseases. Equally important from its central role as the powerhouse of
the cell is the involvement of the mitochondria in cell death
regulation. These two processes are intimately linked by the
generation of reactive oxygen species (ROS) from the mitochondria,
the major contributor of free radicals in the cell. Armed with this
knowledge and from the standpoint of carcinogenesis, the majority of
today's chemotherapeutic drugs are tailored to induce oxidative stress
and bring about ROS-based cell death in the cancer cell through their
effects on the mitochondria. On the other hand, it is well known that
cancer cells have evolved multiple evasive pathways and circuitries to
cheat death. One of these is carried out by the Bcl-2 family of proteins,
consisting of an extensive network of pro- and anti-apoptotic proteins,
of which anti-apoptotic Bcl-2 will be our main focus here. Given its
localization to the mitochondria and its huge stake in mitochondrial
cell death pathway, it would be plausible to suggest Bcl-2 involvement
in mitochondrial physiology. In this review, we seek to redeﬁne the
ﬁeld's current understanding of these areas and provide insights and
implications on the integrative nature of these different aspects of theD9 01-05, Yong Loo Lin School
e 117597. Fax: +65 67788161.
ll rights reserved.mitochondria. More importantly, we aim to draw a link between
mitochondrial metabolism-based ROS production, the resultant
impact on cell death and the role of oncogenic Bcl-2 in controlling
these intricate pathways.
2. ROS and cell death — an intricate balance
Conventional dogma has long established ROS as agents of
detriment. Indeed, a great number of studies have documented the
role of ROS asmediators of damage to cellular structures, nucleic acids,
proteins and lipids. Modiﬁcation of the DNA molecule by ROS
represents the ﬁrst step of mutagenesis and if left unchecked,
carcinogenesis ensues. Lipid peroxidation and protein modiﬁcation
of Bax monomer to promote oligomerization of Bax are common
features of ROS-mediated damage, culminating in the compromise of
the mitochondrial outer membrane integrity and the subsequent
release of cytochrome c to initiate the mitochondrial death pathway
[1]. These form the premise for the use of ROS-based chemother-
apeutics in cancer intervention and management.
While it is true that overwhelming ROS are harmful to cells, an
emergent growing body of evidence indicates the importance of low
levels intracellular ROS in physiological signaling, tumor promotion/
initiation and its subsequent maintenance and progression. There is
sufﬁcient evidence to strongly support a paradigm shift from the
convention of ROS as only a mediator of cell damage/death to that of
survival/proliferation. Mild elevation in intracellular superoxide (O2−)
or hydrogen peroxide (H2O2) has been demonstrated to promote
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growth-related genes such as c-fos and c-jun, alterations in protein
kinase activities, oxidative modiﬁcations to phosphatases and activa-
tion of transcription factors [2,3]. Some of these include ROS
stimulatory effect on the PI3-kinase/AKT survival pathway through
the oxidative inactivation of PTEN as well as activation of transcription
factors such as AP-1 and NF-Kb [4–6]. More importantly, NADPH-
dependent generation of ROS has been reported upon growth factor
stimulation or cytokine receptor activation, implicating ROS as
secondary messengers of survival and proliferative signaling [3,4].
Further studies have gone on to show that the intricate balance
between the different species of free oxygen radicals is important in
determining the decision of the cell fate. A tilt in favor of O2− levels
with no appreciable increase in H2O2 renders the cancer cell refractory
to death execution and preserves viability, irrespective of the trigger
[7–9]. In contrast, increased levels of H2O2 and a corresponding drop
in O2− levels create a reduced and acidiﬁed environment conducive
for the apoptotic signal to ﬁlter through [7]. Correlation between
increased activity of O2− producing systems and proliferative networks
as well as the fact that several anti-cancer drugs exert their effects via
H2O2 mediated killing further lends weight to the pro-oxidant theory
of carcinogenesis, prevalent in many tumor types, depending on the
intracellular levels and species involved.
Thus, mitochondria being a major site of O2− production through
its electron transport chain activities are crucial organelles for the
study on the potential impact of onco-proteins such as Bcl-2 on its
physiology in order to validate the pro-oxidant state, necessary for the
transformed phenotype. However, one confounding factor is the
notion that cancer cells generally exhibit reduced oxidative phos-
phorylation and the next section seeks to address this issue.
3. Altered metabolism and cancer cell fate — one size ﬁts
all theory?
Early studies on tumor metabolism proposed a unique, signature
characteristic in theway these rogue cells obtained their source of ATP
to meet the rigorous demands of proliferation, invasion and adap-
tations to the harsh tumor microenvironment. Back in 1924, Otto
Warburg proposed that cancer cells preferentially utilize the glyco-
lytic pathway over oxidative phosphorylation to provide for the
majority of the energy supply. This is in stark contrast to normal cells
where the reliance on oxidative phosphorylation is far greater than
glycolysis for the generation of ATP. Warburg attributed this
phenomenon to the dysfunction of the mitochondria whereby these
metabolic differences were regarded as an adaptation to the hypoxic
environment within the solid tumor [10].
More than 80 years on, the Warburg effect is widely applied as the
de rigueur metabolic phenomenon to distinguish cancer cells from
non-cancerous ones. The idea that cancer cells predominantly utilize
glycolysis for energy production is being employed as a parameter in
positron emission tomography to assess the prevalence of tumors in
the clinical setting. Indeed, extensive studies have shown that fast-
growing and highly de-differentiated cancer cell types demonstrated
highly modiﬁed metabolic patterns compared to their normal coun-
terparts [11–16]. In agreementwith these observations, a large body of
evidence has emerged suggesting signiﬁcant up-regulation in the
expression of glycolytic genes in aggressive malignancies [17–25].
With these compelling evidence, the concept that enhanced glyco-
lysis is always induced or accompanied by near-defunct oxidative
phosphorylation has been ubiquitously and indiscriminately applied
to all types of cancer. The universal acceptance of the Warburg effect
thus formed the central metabolic dogma that come to characterize all
cancer cells. However, it is important to note that fundamental
genetic, biochemical and morphological heterogeneity of tumor cells
may render the convenient application of theWarburg effect to deﬁne
all types of cancer as generalization. Tumor cell types such asglioblastoma multiforme, astrocytoma, MCF7 and certain forms of
hepatoma utilize both glycolysis and oxidative phosphorylation to an
equal extent for energy production [26–29]. More importantly, tumors
such as bone sarcoma, lung carcinoma, breast cancer, skin melanoma,
cervical, ovarian and uterus carcinomas all primarily make use of
oxidative phosphorylation for the generation of ATP [15,28–32].
Moreover, hypoxia could not entirely justify for the assumption of
compromised oxidative phosphorylation because the concentration of
oxygen in the hypoxic regions of most human tumors is way above the
KM O2 of cytochrome c oxidase (COX) [33]. Therefore, it is likely that
tumor oxidative metabolism remains unaffected by the level of
hypoxia within the tumor microenvironment [33]. Compounded by
evidence taken from fast-growing tumors showing large increase in
glycolytic ﬂux even in the presence of high oxygen concentration, it is
indisputable that all tumor cells possess an increase in glycolytic
capacity but not necessarily in response to a defective oxidative
phosphorylation system [10,12–17,33]. In fact, the demanding ener-
getic needs of the tumor brought on by its highly proliferative nature
may be the main driving force behind the increase in glycolytic ﬂux to
boost the ATP supply, together with an intact oxidative metabolic
pathway [33]. Enhanced tumor glycolysis may be operating in tandem
with oxidative phosphorylation or in some cases; the latter may even
predominate to meet the energy requirements of the highly invasive
tumor [33].
4. Bcl-2, mitoenergetics and cancer cell redox status — a
unique role
4.1. Classical anti-apoptotic role of Bcl-2
Bcl-2 was one of the earliest regulators of apoptosis discovered in
cancer cells, an onco-protein produced via chromosomal translocation
in human follicular lymphoma. Bcl-2 is largely localized to the endo-
plasmic reticulum, nucleus, and the outer membrane of themitochon-
dria. Functional studies on Bcl-2 revealed its pro-survival properties,
mainly through its protective action on the mitochondria. Over the
years, various studies have exhaustively demonstrated the physical
nature of Bcl-2 anti-apoptotic activity, which acts by sequestering pro-
apoptotic proteins such as Bax and Bak at the mitochondria [34,35].
The latter two are responsible for the formation of pores on the
mitochondrial outer membrane through oligomerization and thereby
perturbingmembrane integrity, resulting in the release of cytochrome
c, a key event leading to the eventual activation of the mitochondrial
death pathway [34,35]. Impairment to engage apoptosis to eliminate
cells with malfunctioning cell cycle controls not only preserves these
aberrant cells but also allow metastasis-causing mutations to accu-
mulate and exacerbate their effects. The accrual of mutations further
accentuates the function of Bcl-2 as a death brake, conferring a
heightened level of chemoresistance.
The classical role of Bcl-2 focuses on the interactions between the
two antagonistic classes of proteins from the Bcl-2 family such as anti-
apoptotic Bcl-2/Bcl-xL against pro-apoptotic Bax/Bak, with the bout-
winning proteins deﬁning molecular signaling pathways which
govern several areas from cell death execution to mitochondrial
morphology and physiology [34,35].
4.2. Intrinsic pro-oxidant function of Bcl-2 — involvement
of mitochondria
Several landmark advances have been made to change the ﬁeld's
perspective and to re-evaluate the role of oxidative phosphorylation in
the cancer cell. Notably, functional p53 has been shown to promote
mitochondrial respiration by inducing the expression of Synthesis of
Cytochrome c Oxidase 2 (SCO2), which is responsible for regulating
the COX complex [36]. From the perspective of tumor suppressor p53
where it is often mutated and non-functional in cancer cells, the role
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signated for further investigation from another perspective, that of
ROS andmitoenergetics. Could Bcl-2 replace the role of non-functional
p53 in regulating mitochondrial respiration and contribute to
oncogenesis? Can Bcl-2 preserve or optimize oxidative phosphoryla-
tion to tailor to the survival instincts of the tumor cell from a ROS
perspective? Traditionally, Bcl-2 has been portrayed as an anti-oxidant
due to its ability to suppress H2O2 mediated lipid peroxidation [37].
However, recent work has challenged this belief by demonstrating
that under normal conditions, Bcl-2 did not operate as an anti-oxidant
on its own but rather, its expression levels was directly associated
with a pro-oxidant intracellular milieu that triggered the reinforce-
ment of the endogenous anti-oxidant defense machinery [38]. In turn,
this mild pro-oxidant state was connected to the death inhibitory
activity of Bcl-2 as shown in leukemia cells [39]. Moreover, inhibition
of NADPH oxidase activity by diphenyleneiodonium (DPI) decreased
intracellular O2− and rendered Bcl-2 overexpressing cells more
sensitive to apoptosis, suggesting speciﬁcity for O2− in Bcl-2mediated
pro-oxidant state [39]. Still, other models employing mouse and bac-
teria corroborated our ﬁndings demonstrating Bcl-2 as a pro-oxidant
protein. These reports ﬁrmly established the signiﬁcance of a mild
pro-oxidant milieu in tumor progression/initiation through enhanced
survival, with Bcl-2 at the heart of this phenomenon.
In consideration of Bcl-2 localization at the mitochondria, which is
a major site of ROS production from oxidative phosphorylation, we
demonstrated that Bcl-2 is responsible for promoting tumor mito-
chondrial respiration and in turn, generating a slight pro-oxidant state
through ROS production from electron transport activities [40]. This
slight pro-oxidant state has been shown to favor a cascade of survival
signaling pathways in cancer cells [38,39,41–43]. Bcl-2 which is
almost ubiquitous at the mitochondria has rarely been linked to the
bioenergetics aspect of the mitochondria. For the ﬁrst time, by mea-
suring the enzymatic activity of cytochrome c oxidase (COX) which is
the rate-limiting complex of the electron transport chain, leukemia
cells (CEM) overexpressing Bcl-2 displayed an increase in COX activity
and oxygen consumption, which associated with an increase in
mitochondrial O2− production [40]. Similar observations were
obtained in a cervical carcinoma (HeLa) model [40]. Bcl-2 over-
expressing tumor cells not only displayed elevated oxygen consump-
tion but also better coupled mitochondrial respiration, suggesting that
the increase in O2− generation is indeed a function of ampliﬁed
mitochondrial respiration and not due to uncoupling [40]. Despite
treatment of mock-transfected and Bcl-2 overexpressing cells with the
uncoupler FCCP, cells with Bcl-2 overexpression continued to display
higher oxygen consumption [40]. Increased mitochondrial respiration
suggests an increased tendency to leak electrons for the generation of
O2− as a by-product.
Transient overexpression and silencing of Bcl-2 correlated with the
presence and absence of the pro-oxidant effect respectively [40].
Similarly, reduction of electron transport activities through the partial
inhibition of COX was able to abrogate O2− levels in Bcl-2 expressing
cells to that of non-transfected cells, further validating the impact of
Bcl-2 on the pro-oxidant state through mitochondrial respiration [40].
Although HA14-1, which is a well-known Bcl-2 inhibitor, has been
shown to induce oxidative stress in treated cells, functional inhibition
of Bcl-2 led to a reduction in oxygen consumption [40].
4.3. Anti-oxidant function — two faces of Bcl-2?
In spite of conventional acceptance of Bcl-2 as an anti-oxidant, a
growing number of studies indicate that the enhanced anti-oxidant
cellular defense is a response to the pro-oxidant capability of Bcl-2 and
could be crucial in protecting the cell from acute oxidative stress.
Various experimental models established the anti-oxidant property of
Bcl-2 by triggering cells with death-inducing stimuli or directly over-
whelming the cells with oxidative stress before accruing the resultantanti-oxidant response to Bcl-2 expression. At best, these studies
accredit a redox regulatory role for Bcl-2 in countering oxidative
stress, but do not sufﬁce to conﬁrm Bcl-2 as having innate anti-oxidant
characteristics. True to this aspect, pure Bcl-2 has been shown to be
devoid of intrinsic anti-oxidant activity [44]. Hence, while Bcl-2 may
be pro-oxidant under normal, non-stressed conditions, triggers indu-
cing acute oxidative stress may activate the feedback function of Bcl-2
to fortify anti-oxidant defenses and thus, prevent levels of free radicals
from breaching deleterious level. In view of this, our recent data
propose a control by Bcl-2 at the level of mitochondrial bioenergetics
by tuning COX activity to modify upstream electron transport chain
activities, which in turn, affect the level of ROS by-production from
oxidative phosphorylation.
Using both physiological and artiﬁcial triggers-induced stress
approach, early mitochondrial oxidative stress insult by antimycin or
serum deprivation led to a down-regulation of COX activity and
oxygen consumption in tumor cells overexpressing Bcl-2 [40]. In
contrast, similarly treated mock-transfected cells displayed increases
in COX activity and oxygen consumption [40]. This observation
corresponded to the maintenance of mitochondrial O2− levels in the
Bcl-2 cells while the levels in non-overexpressing cells continue to
accumulate after the initial oxidative burst [40]. Although treatment
with rotenone also resulted in an increase in COX activity in Bcl-2 cells,
the magnitude of increase was much lower than the control cells [40].
This could be attributed to the fact that antimycin blockade of complex
III results in production of O2− to the mitochondrial intermembrane
space whereas rotenone inhibition of complex I results in accumula-
tion of O2− in the mitochondrial matrix [45]. This disparity may
account for the difference in Bcl-2 efﬁciency to ‘sense’ oxidative stress
and regulate COX activity accordingly. Nonetheless, it appears that
Bcl-2 regulation on COX activity during normal conditions and in
response to oxidative stress does not involve any change in the levels
of expression of COX subunits.
These unique ﬁndings suggest a novel feature of Bcl-2 that steers
away from the ﬁeld's conventional knowledge of the protein by
focusing on the regulation of mitochondrial ROS production via its
metabolic control on COX activity.With this inmind, an increase in Bcl-
2 expression might be a double-edged sword, counteracting against
cell death machinery by enhancing energy production as well as
generating more O2− as a by-product to provide a slight pro-oxidant,
survival-inclined milieu, on top of its established anti-apoptotic
functions. Investigations reporting the anti-oxidant function of Bcl-2
could be due to the physiological role of Bcl-2 as a ROSmodulator [41].
These studies provided an alternative opinion of ROS, away from the
classical notion of detriment to amore astute and discerning viewof its
effects in carcinogenesis that is dependent on the levels and species
involved, particularly the implication of O2− in tumor cell survival.
On the contrary, physiological stress stimuli or chemical ROS
inducers triggered a homeostatic response from Bcl-2 to reduce
mitochondrial respiration through the rate-limiting, terminal enzyme
COX; hence, preventing the buildup of O2− to a lethal level after the
early insult, while possibly striving to sustain the basal energy
requirement and slight pro-oxidant milieu necessary for survival [40]
(Fig. 1). Ongoing studies seem to advocate the promise of Bcl-2 ability
to optimize both the energetic demands and redox status of the cancer
cell by adapting mitochondrial metabolism so as to craft an environ-
ment best suited for survival and proliferation. However, the exact
molecular mechanism remains unknown.
4.4. Bcl-2, p53 and HIF-1 in relation to ROS and metabolic adaptation
Recently, several reports have emerged implicating various key
proteins to cancer metabolism. More notably, HIF-1 has been
demonstrated to play a central role in regulating the efﬁciency of
mitochondrial respiration during hypoxia via its effect on altering the
COX subunits' composition by transactivating COX-4-2 and LON
Fig. 1. Bcl-2 regulation of tumor redox states is mediated through its effect on mitochondrial respiration, which suggests an alternative oncogenic mechanism employed by Bcl-2.
Oxidative stress serves as a negative feedback by signaling via Bcl-2 to decrease mitochondrial respiration.
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efﬁciency in mitochondrial respiration with a control on ROS produc-
tion from the initial burst generated by hypoxia. A major stakeholder
in the cancer ﬁeld, p53 is able to promote mitochondrial respiration
while keeping ROS in check by inducing the transcription of anti-
oxidant genes during low-stress state of normal growth and deve-
lopment [47,48]. In times of extended stress and irreparable damage,
stress-induced p53 is able to up-regulate pro-oxidant genes such as
PIG-3 and proline oxidase as well as down-regulate anti-oxidant
enzymes such as the Nrf-2 dependent ones along with driving up the
activation of mitochondrial respiration, in order to induce p53-
dependent cell death by ROS, thus removing aberrant cells from
transforming into rogue cancerous cells [36,49–52].
Thus, while the normal cell type relies on p53 for normal
mitochondrial and redox regulation during different growth condi-Fig. 2. Comparison between p53 andtions, the transformed phenotype which often contains the loss-of-
function mutant p53 and high levels of Bcl-2, may possess an entirely
different set of metabolic regulation which favors a survival-inclined
oxidant level and energy production by employing Bcl-2 as a rheostat
acting on mitochondrial respiration during normal and stress
conditions [40,48] (Fig. 2). The fact that p53 is an upstream repressor
of Bcl-2 expression lends further credit to this theory with regard to
their opposing roles through employing different strategies on a single
mechanism to achieve their means in normal and cancerous cells
respectively.
The link between Bcl-2 and tumor mitochondrial metabolism also
begs the question if it is closely connected to HIF-1 action on COX.
Studies have shown that silencing of HIF-1α under normoxia or
hypoxia correlated with decreased expression of Bcl-2 and subse-
quent attenuation in cell proliferation and induction of apoptosisBcl-2 regulated mitoenergetics.
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between resistance to hypoxia-induced apoptosis and increased Bcl-
2 expression [54]. In addition, overexpression of HIF-1α in
combination with Bcl-2 resulted in poor treatment outcome in
esophageal cancer [55]. However, it remains to be seen whether
these two proteins are indeed linked or merely correlative, with
each having its own unique repertoire of mechanisms to bring
about a common purpose of tumor metabolic regulation. Never-
theless, the intricate controls on tumor mitochondrial respiration
and oxidative phosphorylation by onco-proteins and tumor sup-
pressors cannot be denied. Tumors that are able to harness energy
from both enhanced glycolysis and oxidative phosphorylation,
fashion a redox environment favoring the transformed phenotype
and display extensive metabolic plasticity and adaptability under
different redox state to provide a survival edge over their counter-
parts that simply rely on ampliﬁed glycolytic ﬂux and compromised
oxidative phosphorylation.
4.5. Redox regulation by Bcl-2 and ROS-based chemotherapeutics
Moderate levels of ROS are obligatory by-products of cellular
metabolism and indispensable for normal cellular growth and
functions. On the other hand, excessive ROS production leads to
severe compromise of cellular structures and integrity, which even-
tually brings about the demise of the cell. Based on this principle,
many anti-tumor agents were developed including doxorubicin,
cisplatin and vinblastine among many others, in the hope of
exerting their anti-tumor effect through ROS-dependent induction
of apoptotic cell death [56]. Many of these agents aim to induce
massive ROS production either directly or via the inhibition of
cellular anti-oxidant defenses. More recently, these compounds have
been further developed to enhance their tumor-targeting speciﬁcity,
in order to avoid severe side effects and improve drug efﬁcacy [56].
In view of this, high Bcl-2 expression may affect the efﬁcacy of
these ROS-inducing anti-tumor agents not only through inhibition of
apoptotic cell death but also via direct regulation of the resultant
oxidative stress through mitochondrial metabolic pathways, keeping
the redox status constant while obliterating the death-inducing levels
of ROS from these anti-tumor agents.
The discovery of this non-canonical function of Bcl-2 presents a
paradigm shift in the understanding of tumor metabolism as well as
the conventional roles that onco-proteins were expected to play in
carcinogenesis. More importantly, it further underscores the impor-
tance of Bcl-2 inhibitors-based drug therapies as well as the
signiﬁcance of Bcl-2 expression levels in various tumors, which will
deﬁne their metabolic and ROS proﬁles. These may prove to be
predictive of the efﬁcacy of ROS and metabolic-based therapies,
whereby the inherent level of Bcl-2 expression may determine the
treatment prognosis of the tumor. In this respect, Bcl-2 and
mitochondrial metabolism come across as attractive therapeutic
targets in the treatment of cancer.
5. Conclusion
Despite numerous reports implicating Bcl-2 as an anti-oxidant, a
growing body of evidence clearly indicates Bcl-2 as a pro-oxidant with
no intrinsic anti-oxidant properties under normal conditions. How-
ever, during oxidative stress conditions, apart from the heightened
anti-oxidant defense response previously reported, Bcl-2 is also able
tomodulate mitochondrial respiration by regulating the activity of the
rate-limiting, terminal enzyme COX to bring about an overall reduc-
tion in the by-production of O2−, keeping levels of ROS from reaching
the point of detriment. With the increasing debate over the role of Bcl-
2 as an anti- or pro-oxidant, the homeostatic behavior of Bcl-2 that we
now understand, may justify and reconcile both schools of thought.
This novel understanding of Bcl-2 extends its classical anti-apoptoticrole into the realm of mitochondrial metabolism and redox biology,
where its involvement further accentuates neoplastic progression and
maintenance.
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